← Leaderboards
Jean Bennett
University Of Pennsylvania
$11,682,679
Attributed
$12,242,638
Total exposure
11
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$12,242,638 · 11
By mechanism
R01$5,244,861 · 2
DP1$3,974,800 · 2
R21$821,155 · 2
T32$689,954 · 1
P01$614,667 · 1
P30$501,773 · 1
Top collaborators
- Diego Contreras5 shared
- Mitchell Lewis2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- William A. Beltran$14,525,140
- Mitchell Lewis$7,042,975
- Eric A Pierce$25,662,965
- Gustavo David Aguirre$22,398,317
- Susanna Maxwell Lewis$428,000
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyVisionGene MutationRetinaLaboratory MouseRetinal DiseasesIn Situ HybridizationPolymerase Chain ReactionRetinitis PigmentosaDesignIn VivoResearch PersonnelElectroretinographyRetinalBaseAnimal ModelResponseMediatingMouse ModelMacular DegenerationTranslational ResearchInheritedIn VitroImmunocytochemistry
Grant awards (39)
Research on normal and abnormal mechanisms of vision$161,429
T32 · FY2023 · EY
Research on normal and abnormal mechanisms of vision$131,564
T32 · FY2022 · EY
Research on normal and abnormal mechanisms of vision$139,878
T32 · FY2021 · EY
Research on normal and abnormal mechanisms of vision$135,652
T32 · FY2020 · EY
Spectralis Tracking HRA-Optical Coherence Tomography 2 (OCT2): Advanced Ophthalmic Imaging for Small and Large Animal Studies$238,640
S10 · FY2019 · OD · contact PI
Research on normal and abnormal mechanisms of vision$121,431
T32 · FY2019 · EY
Noninvasive Assessment Module$102,910
P30 · FY2019 · EY · contact PI
Noninvasive Assessment Module$102,910
P30 · FY2018 · EY · contact PI
Noninvasive Assessment Module$102,910
P30 · FY2017 · EY · contact PI
An Inducible System for Gene Delivery$194,982
R21 · FY2016 · EB
Noninvasive Assessment Module$102,910
P30 · FY2016 · EY · contact PI
Broad Spectrum Molecular Therapy for Blinding Retina Disorders$800,000
DP1 · FY2015 · EY · contact PI
An Inducible System for Gene Delivery$234,982
R21 · FY2015 · EB
Noninvasive Assessment Module$90,133
P30 · FY2015 · EY · contact PI
Broad Spectrum Molecular Therapy for Blinding Retina Disorders$800,000
DP1 · FY2014 · EY · contact PI
Broad Spectrum Molecular Therapy for Blinding Retina Disorders$774,800
DP1 · FY2013 · EY · contact PI
Broad Spectrum Molecular Therapy for Blinding Retina Disorders$800,000
DP1 · FY2012 · EY · contact PI
Broad Spectrum Molecular Therapy for Blinding Retina Disorders$800,000
DP1 · FY2011 · OD · contact PI
Gene Therapy for Usher Syndrome (USH1C)$194,316
R21 · FY2008 · DC · contact PI
Gene Therapy for Inherited Retinal Degeneration$366,679
R01 · FY2007 · EY · contact PI
Gene Therapy for Usher Syndrome (USH1C)$196,875
R21 · FY2007 · DC · contact PI
AAV-mediated gene correction in retina$78,288
R03 · FY2007 · EY · contact PI
Gene Therapy for Inherited Retinal Degeneration$368,744
R01 · FY2006 · EY · contact PI
AAV-mediated gene correction in retina$78,500
R03 · FY2006 · EY · contact PI
Gene Therapy for Inherited Retinal Degeneration$377,618
R01 · FY2005 · EY
Animal Model for a Hereditary Macular Degeneration$387,863
R01 · FY2004 · EY
Gene Therapy for Inherited Retinal Degeneration$377,618
R01 · FY2004 · EY
Gene Therapy for Inherited Retinal Degeneration$392,243
R01 · FY2003 · EY
Animal Model for a Hereditary Macular Degeneration$388,108
R01 · FY2003 · EY
GENETIC THERAPY FOR HEREDITARY RETINAL DEGENERATIONS$395,223
R01 · FY2002 · EY
Animal Model for a Hereditary Macular Degeneration$388,345
R01 · FY2002 · EY
STUDIES OF PLATELET ADHERENCE TO OSTEOPONTIN$175,153
P01 · FY2002 · HL
GENETIC THERAPY FOR HEREDITARY RETINAL DEGENERATIONS$593,116
R01 · FY2001 · EY
Animal Model for a Hereditary Macular Degeneration$376,290
R01 · FY2001 · EY
STUDIES OF PLATELET ADHERENCE TO OSTEOPONTIN$175,153
P01 · FY2001 · HL
GENETIC THERAPY FOR HEREDITARY RETINAL DEGENERATIONS$363,119
R01 · FY2000 · EY
STUDIES OF PLATELET ADHERENCE TO OSTEOPONTIN$264,361
P01 · FY2000 · HL
GENETIC THERAPY FOR HEREDITARY RETINAL DEGENERATIONS$247,336
R01 · FY2000 · EY
ANIMAL MODELS FOR A HEREDITARY MACULAR DEGENERATON$222,559
R01 · FY2000 · EY